Use of primary high-risk human papillomavirus testing for cervical cancer screening: Interim clinical guidance

    Authors

    W. K. Huh; K. A. Ault; D. Chelmow; D. D. Davey; R. A. Goulart; F. A. R. Garcia; W. K. Kinney; L. S. Massad; E. J. Mayeaux; D. Saslow; M. Schiffman; N. Wentzensen; H. W. Lawson;M. H. Einstein

    Comments

    Authors: contact us about adding a copy of your work at STARS@ucf.edu

    Abbreviated Journal Title

    Gynecol. Oncol.

    Keywords

    LIQUID-BASED CYTOLOGY; FOLLOW-UP; WOMEN; TRIAL; COLPOSCOPY; PREVENTION; SERVICES; FINLAND; Oncology; Obstetrics & Gynecology

    Abstract

    In 2011, the American Cancer Society, the American Society for Colposcopy and Cervical Pathology, and the American Society for Clinical Pathology updated screening guidelines for the early detection of cervical cancer and its precursors. Recommended screening strategies were cytology and cotesting (cytology in combination with hrHPV testing). These guidelines also addressed the use of hrHPV testing alone as a primary screening approach, which was not recommended for use at that time. There is now a growing body of evidence for screening with primary hrHPV testing, including a prospective US-based registration study. Thirteen experts including representatives from the Society of Gynecologic Oncology, American Society for Colposcopy and Cervical Pathology, American College of Obstetricians and Gynecologists, American Cancer Society, American Society of Cytopathology, College of American Pathologists, and the American Society for Clinical Pathology, convened to provide interim guidance for primary hrHPV screening. This guidance panel was specifically triggered by an application to the FDA for a currently marketed HPV test to be labeled for the additional indication of primary cervical cancer screening. Guidance was based on literature review and review of data from the FDA registration study, supplemented by expert opinion. This document aims to provide information for healthcare providers who are interested in primary hrHPV testing and an overview of the potential advantages and disadvantages of this strategy for screening as well as to highlight areas in need of further investigation. (C) 2014 the Society of Gynecologic Oncology and the American Society for Colposcopy and Cervical Pathology. Published by Elsevier Inc. All rights reserved.

    Journal Title

    Gynecologic Oncology

    Volume

    136

    Issue/Number

    2

    Publication Date

    1-1-2015

    Document Type

    Editorial Material

    Language

    English

    First Page

    178

    Last Page

    182

    WOS Identifier

    WOS:000350527500002

    ISSN

    0090-8258

    Share

    COinS